{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-030413","form_type":"8-K","ticker":"PPCB","cik":"0001517681","company_name":"Propanc Biopharma, Inc.","filed_at":"2023-08-29T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.171570+00:00","generated_at":"2026-06-11T02:22:45.524850+00:00","sec_items":["1.01","2.03","3.02","9.01"],"event_type":"debt","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Propanc Biopharma raises $72,500 via convertible note with aggressive conversion terms","bullets":["$77,500 convertible note issued to GS Capital Partners; net proceeds $72,500, 8% interest, matures Feb 2024.","Initial conversion price $0.04/share; drops to $0.02 if stock trades below $0.03 for five consecutive days.","Company may prepay at 110%-125% premium within 180 days; after that no prepayment right.","Proceeds for general working capital; note issued under Regulation D, unregistered.","Default triggers 24% interest and potentially lower conversion price based on lowest trading price."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-030413","json":"https://secwatch.observer/filing/0001493152-23-030413.json","markdown":"https://secwatch.observer/filing/0001493152-23-030413.md","text":"https://secwatch.observer/filing/0001493152-23-030413.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1517681/000149315223030413/0001493152-23-030413-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1517681/000149315223030413/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T02:22:45.524850+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"22a8579cf6fc7cbdc700fff0d30d517bbb91c7b2","claim":"Propanc Biopharma, Inc. incurred convertible notes of $77,500 with an investor at 8% per annum maturing February 23, 2024.","evidence_excerpt":"On August 23, 2023, Propanc Biopharma, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with an investor (the “Investor”), which closed on August 23, 2023, pursuant to which the Investor purchased a convertible redeemable promissory note in the aggregate principal amount of $77,500 (the “Note”) from the Company for $72,500.","evidence_source":"SEC 8-K Item 2.03/2.04","evidence_url":"https://www.sec.gov/Archives/edgar/data/1517681/000149315223030413/0001493152-23-030413-index.htm","confidence":0.9,"family_label":"Debt Financings","details":[{"label":"Instrument","value":"convertible notes"},{"label":"Principal","value":"$77,500"},{"label":"Counterparty","value":"an investor"},{"label":"Rate","value":"8% per annum"},{"label":"Maturity","value":"February 23, 2024"},{"label":"Event","value":"incurrence"}],"fact_type":"debt_financing"},{"claim_id":"629946b02122b475d2ee3b84c2c9a415d2c816b2","claim":"Propanc Biopharma, Inc. entered into Purchase Agreement with an investor (the “Investor”) valued at $77,500 (effective 2023-08-23).","evidence_excerpt":"On August 23, 2023, Propanc Biopharma, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with an investor (the “Investor”), which closed on August 23, 2023, pursuant to which the Investor purchased a convertible redeemable promissory note in the aggregate principal amount of $77,500","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1517681/000149315223030413/0001493152-23-030413-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"an investor (the “Investor”)"},{"label":"Value","value":"$77,500"},{"label":"Effective","value":"2023-08-23"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}